| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | GCAT2; Gcet; Gcsam; hGAL; M17; M17 L |
| Entrez GeneID | 257144 |
| WB Predicted band size | Calculated MW: 21 kDa; Observed MW: 21 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Recombinant protein of human GCET2 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于GCET2抗体的3篇参考文献示例(注：文献信息为虚构示例，实际文献需通过学术数据库检索确认)：
1. **文献名称**：*"GCET2 as a novel biomarker in diffuse large B-cell lymphoma: Expression profiling and clinical significance"*
**作者**：Zhang L, et al.
**摘要**：本研究通过免疫组织化学分析GCET2在弥漫大B细胞淋巴瘤(DLBCL)中的表达，发现GCET2高表达与生发中心B细胞样(GCB)亚型显著相关，提示其可作为DLBCL分型的潜在标志物。
2. **文献名称**：*"Development of a monoclonal antibody against GCET2 for diagnostic applications in lymphoid malignancies"*
**作者**：Tanaka K, et al.
**摘要**：报道了一种特异性识别GCET2蛋白的单克隆抗体的开发与验证，该抗体在石蜡包埋组织中表现出高灵敏度和特异性，可用于区分DLBCL的不同分子亚型。
3. **文献名称**：*"GCET2/SERPINA9 regulates B-cell survival and its role in lymphomagenesis"*
**作者**：Wang Y, et al.
**摘要**：探讨GCET2(SERPINA9)在生发中心B细胞存活中的作用，通过抗体介导的功能实验发现其过表达可能抑制凋亡，促进淋巴瘤发生。
建议通过PubMed、Web of Science等平台以关键词“GCET2 antibody”、“SERPINA9 lymphoma”或“GCET2 biomarker”检索真实文献。
**Background of GCET2 Antibody**
The GCET2 (Germinal Center B-cell Expressed Transcript 2) antibody targets the GCET2 protein, also known as *sialyltransferase 8A (SIAT8A)* or *ST8SIA1*, a member of the sialyltransferase family. This protein is predominantly expressed in germinal center (GC) B-cells and plays a role in modulating cell-surface glycosylation, which influences cell signaling, adhesion, and immune responses.
GCET2 gained attention as a biomarker for classifying diffuse large B-cell lymphomas (DLBCLs). DLBCLs are heterogeneous, with subtypes including germinal center B-cell-like (GCB) and activated B-cell-like (ABC) groups. GCET2. along with other markers like CD10 and BCL6. is highly expressed in the GCB subtype, aiding in molecular subtyping via immunohistochemistry (IHC) or gene expression profiling. This distinction is clinically relevant, as GCB-DLBCL generally has a better prognosis than ABC-DLBCL when treated with standard therapies like R-CHOP.
The GCET2 antibody is widely used in research and diagnostics to study B-cell development, lymphomagenesis, and tumor microenvironments. Its specificity for GC-derived cells makes it valuable for investigating GC-related malignancies and immune disorders. However, its utility may be context-dependent, requiring validation with complementary markers to ensure accurate classification. Ongoing research explores its role in disease mechanisms and potential therapeutic targeting.
×
